Five Prime Therapeutics Reports Third Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St recovers as yields ease; Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Five Prime Therapeutics (FPRX) Misses Q3 EPS by 8c
November 6, 2019 5:29 PM ESTFive Prime Therapeutics (NASDAQ: FPRX) reported Q3 EPS of ($1.03), $0.08 worse than the analyst estimate of ($0.95). Revenue for the quarter came in at $2.98 million versus the consensus estimate of $5.23 million.
We have advanced all of our wholly-owned programs according to our plan for 2019, said William... More
